| Autor: |
Knapp, D. W., Filion, B., Filion, M. C., Phillips, N. C. |
| Předmět: |
|
| Zdroj: |
Veterinary & Comparative Oncology; Mar2005, Vol. 3 Issue 1, p46-47, 2p |
| Abstrakt: |
Mycobacterial cell wall-DNA complex(MCC) is a bifunctional anticancer agent that induces cancer cell apoptosis and stimulates cytokine synthesis by immune cells. Intravesical MCC is currently being evaluated in humans with high-grade urinary bladder cancer. Evaluation of MCC in dogs with transitional cell carcinoma(TCC) will allow mechanistic studies in a natural animal model of TCC, and a potentially beneficial therapy for dogs with this cancer. In this study, we have determined the anticancer activity of MCC against canine TCC cellsin vitro.Canine TCC cells(K9TCC cell line) were incubated with MCC(0.05–100 μg/ml, 0.5–72 hours). Cellular proliferation was measured by MTT reduction. Cell cycle was analyzed by flow cytometry with propidium iodide. Apoptosis was identified by flow cytometry using anti-active-caspase-3/PE and anti-cleaved-PARP/FITC antibodies. Apoptosis-inducing activity of 100 μg/ml MCC in combination with piroxicam(0.1–1.0 uM) was evaluated.MCC inhibited K9TCC cell proliferation in a concentration-dependent manner(maximal activity– 45% at 100 μg/ml MCC) in association with the presence of activated caspase-3 and cleaved PARP. Inhibition of proliferation and apoptosis-inducing activities of MCC were independent of cell cycle phase. A thirty-minute exposure of MCC was sufficient for optimal activity. Piroxicam(0.5 uM) enhanced apoptosis-inducing activity of MCC.MCC induces apoptosis in K9TCC cells. This activity is potentiated by piroxicam. Following positive resultsin vitro,in vivostudies have been initiated. One dog, treated to date, has had a minor reduction in tumor volume following the first course of treatment with no treatment-related toxicity. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
